5-羟甲基胞嘧啶与肿瘤

doi:10.11904/j.issn.1002-3070.2021.04.017

Abstract

Abstract: The occurrence,development and invasion of tumors are closely related to epigenetic changes.5-Methylcytosine(5-mC),a product of cytosine methylation,is an important epigenetic regulator.Hydroxymethylation is one of the important processes of 5-mC demethylation,and its product 5-hydroxymethylcytosine(5-hmC)is also involved in the epigenetic regulation of genes.Multiple studies at domestic and foreign suggest that the changes of 5-hmC level and distribution are closely related to embryonic development and tumorigenesis.This article reviews the research progress of 5-hmC and its abnormality in tumor and its relationship with tumor.

Key words: Tumor, DNA hydroxymethylation, 5-Hydrosymethylcytosine

CLC Number:

R730.43

LIU Shuangqing, CHE Dehai, MENG Qingwei. 5-Hydroxymethylcytosine and tumor[J]. Journal of Practical Oncology, 2021, 35(4): 386-390.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2021.04.017

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2021/V35/I4/386

References

1 Yu M,Hazelton WD,Luebeck GE,et al.Epigenetic aging:more than just a clock when it comes to cancer[J].Cancer Res,2020,80(3):367-374.
2 Kumar S,Chinnusamy V,Mohapatra T.Epigenetics of modified DNA bases:5-methylcytosine and beyond[J].Front Genet,2018,9:640.
3 Wu X,Zhang Y.TET-mediated active DNA demethylation:mechanism,function and beyond[J].Nat Rev Genet,2017,18(9):517-534.
4 Li W,Xu L.Epigenetic function of TET family,5-methylcytosine,and 5-hydroxymethylcytosine in hematologic malignancies[J].Oncol Res Treat,2019,42(6):309-318.
5 Pfeifer GP,Szabó PE,Song J.Protein interactions at oxidized 5-methylcytosine bases[J].J Mol Biol,2019,2836(19)30501-30507.
6 Kohli RM,Zhang Y.TET enzymes,TDG and the dynamics of DNA demethylation[J].Nature,2013,502(7472):472-479.
7 Kochmanski J,Bernstein AI.The impact of environmental factors on 5-hydroxymethylcytosine in the brain[J].Curr Environ Health Rep,2020,7(2):109-120.
8 López V,Fernández AF,Fraga MF.The role of 5-hydroxymethylcytosine in development,aging and age-related diseases[J].Ageing Res Rev,2017,37:28-38.
9 Smeets E,Lynch AG,Prekovic S,et al.The role of TET-mediated DNA hydroxymethylation in prostate cancer[J].Mol Cell Endocrinol,2018,462:41-55.
10 Wang J,Su Y,Tian Y,et al.Characterization of DNA hydroxymethylation profile in cervical cancer[J].ARTIF Cell Nanomed B,2019,47(1):2706-2714.
11 Kristensen G,Strand SH,Røder MA,et al.5hmC level predicts biochemical failure following radical prostatectomy in prostate cancer patients with ERG negative tumors[J].Int J Mol Sci,2019,20(5):1025.
12 Bonvin E,Radaelli E,Bizet M,et al.TET2-dependent hydroxymethylome plasticity reduces melanoma initiation and progression[J].Cancer Res,2019,79(3):482-494.
13 Cai J,Chen L,Zhang Z,et al.Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma[J].Gut,2019,68(12):2195-2205.
14 Wu J,Li H,Shi M,et al.TET1-mediated DNA hydroxymethylation activates inhibitors of the Wnt/beta-catenin signaling pathway to suppress EMT in pancreatic tumor cells[J].J Exp Clin Cancer Res,2019,38(1):348.
15 Li X,Liu Y,Salz T,et al.Whole-genome analysis of the methylome and hydroxymethylome in normal and malignant lung and liver[J].Genome Res,2016,26(12):1730-1741.
16 Chen Q,Yin D,Zhang Y,et al.MicroRNA-29a induces loss of 5-hydroxymethylcytosine and promotes metastasis of hepatocellular carcinoma through a TET-SOCS1-MMP9 signaling axis[J].Cell Death Dis,2017,8(6):e2906.
17 Lian CG,Xu Y,Ceol C,et al.Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma[J].Cell,2012,150(6):1135-1146.
18 Peng D,Ge G,Gong Y,et al.Vitamin C increases 5-hydroxymethylcytosine level and inhibits the growth of bladder cancer[J].Clin Epigenetics,2018,10(1):94.
19 Shi DQ,Ali I,Tang J,et al.New insights into 5hmc DNA modification:generation,distribution and function[J].Front Genet,2017,8:100.
20 Mahajan NP,Malla P,Bhagwat S,et al.WEE1 epigenetically modulates 5-hmC levels by pY37-H2B dependent regulation of IDH2 gene expression[J].Oncotarget,2017,8(63):106352-106368.
21 Fu S,Wu H,Zhang H,et al.DNA methylation/hydroxymethylation in melanoma[J].Oncotarget,2017,8(44):78163-78173.
22 Liu J,Jiang J,Mo J,et al.Global dna 5-hydroxymethylcytosine and 5-formylcytosine contents are decreased in the early stage of hepatocellular carcinoma[J].Hepatology,2019,69(1):196-208.
23 Wang P,Yan Y,Yu W,et al.Role of ten-eleven translocation proteins and 5-hydroxymethylcytosine in hepatocellular carcinoma[J].Cell Prolif,2019,52(4):e12626.
24 Song CX,Yin S,Ma L,et al.5-Hydroxymethylcytosine signatures in cell-free DNA provide information about tumor types and stages[J].Cell Res,2017,27(10):1231-1242.
25 Zhang J,Han X,Gao C,et al.5-Hydroxymethylome in circulating cell-free DNA as a potential biomarker for non-small-cell lung cancer[J].Genom Proteom Bioinf,2018,16(3):187-199.
26 Fernandez AF,Bayón GF,Sierra MI,et al.Loss of 5hmC identifies a new type of aberrant DNA hypermethylation in glioma[J].Hum Mol Genet,2018,27(17):3046-3059.
27 Zhou Z,Zhang HS,Liu Y,et al.Loss of TET1 facilitates DLD1 colon cancer cell migration via H3K27me3-mediated down-regulation of E-cadherin[J].J Cell Physiol,2018,233(2):1359-1369.
28 Che D,Zhang S,Jing Z,et al.Macrophages induce EMT to promote invasion of lung cancer cells through the IL-6-mediated COX-2/PGE(2)/β-catenin signalling pathway[J].Mol Immunol,2017,90:197-210.
29 Ko M,An J,Pastor WA,et al.TET proteins and 5-methylcytosine oxidation in hematological cancers[J].Immunol Rev,2015,263(1):6-21.
30 Hore TA,Von Meyenn F,Ravichandran M,et al.Retinol and ascorbate drive erasure of epigenetic memory and enhance reprogramming to nave pluripotency by complementary mechanisms[J].Proc Natl Acad Sci U S A,2016,113(43):12202-12207.
31 Li C,Dong L,Su R,et al.Homoharringtonine exhibits potent anti-tumor effect and modulates DNA epigenome in acute myeloid leukemia by targeting SP1/TET1/5hmC[J].Haematologica,2020,105(1):148-160.
32 Lio CJ,Yuita H,Rao A.Dysregulation of the TET family of epigenetic regulators in lymphoid and myeloid malignancies[J].Blood,2019,134(18):1487-1497.
33 Shenoy N,Bhagat TD,Cheville J,et al.Ascorbic acid-induced TET activation mitigates adverse hydroxymethylcytosine loss in renal cell carcinoma[J].J Clin Invest,2019,129(4):1612-1625.

[1]	LIU Yanyu, LI Daojuan, LIANG Di, SHI Jin, JIN Jing, SHAN Baoen, HE Yutong. An analysis of the incidence and mortality of esophageal cancer in Hebei cancer registration area from 2011 to 2016 [J]. Journal of Practical Oncology, 2021, 35(4): 314-320.
[2]	WANG Qin, LIN Ling, CAI Bo, TAO Changyu, WU Ming, HAN Renqiang, LUO Pengfei, YU Hao, MIAO Weigang, ZHOU Jinyi. Epidemic status of brain and nervous system tumors in Jiangsu province in 2015 and trend analysis from 2006 to 2015 [J]. Journal of Practical Oncology, 2021, 35(4): 321-326.
[3]	WU Jing, CUI Wangfei, CAO Ling, GUO Xuerong, MA Zhaohui, WANG Xinchen, ZHANG Ruifeng, ZHANG Yongzhen. Analysis for the incidence and death of upper gastrointestinal cancer in the cancer registration areas of Shanxi province in 2016 [J]. Journal of Practical Oncology, 2021, 35(4): 327-331.
[4]	DONG Hua, WANG Dingbin, HUA Jing, FAN Kangqiong, MA Nannan, WANG Xingren. Analysis for the incidence and death of malignant tumors in Hainan cancer registry,2016 [J]. Journal of Practical Oncology, 2021, 35(4): 344-350.
[5]	CHEN Lili, LIU Yuqin, DING Gaoheng, SU Haixiang. Epidemic situation about prevention and control of malignant tumor in Gansu province [J]. Journal of Practical Oncology, 2021, 35(3): 254-257.
[6]	MA Mingrui, LIAN Jie, LIU Chao, LOU Changjie, ZHANG Yanqiao. Exploration of “immunotherapy moving forward” for digestive system tumors [J]. Journal of Practical Oncology, 2021, 35(3): 258-262.
[7]	LI Min, RAN Li, CHANG Jianying. Application of imaging technology in image-guided brachytherapy for cervical cancer [J]. Journal of Practical Oncology, 2021, 35(3): 263-267.
[8]	SHI Yuanyang, LIU Jiaren. Research progress in anticancer activity of β-ionone [J]. Journal of Practical Oncology, 2021, 35(3): 268-272.
[9]	GUO Haonan, QIN Tao. Research progress of MYO10 and malignant tumors [J]. Journal of Practical Oncology, 2021, 35(3): 273-276.
[10]	PAN Hongyan, LI Aiping, LI Qiang. Research progress of the correlation between adipokine omentin-1 and tumor [J]. Journal of Practical Oncology, 2021, 35(3): 282-286.
[11]	WANG Mengmeng, LIAN Jie, LI Hengzhen, ZHANG Yanqiao. Research progress in immunotherapy of gastrointestinal pancreatic neuroendocrine tumors [J]. Journal of Practical Oncology, 2021, 35(2): 154-159.
[12]	YIN Qi, HU Yanjian, CUI Puze, HU Yanhua. Research progress of Notch signaling pathway in regulating apoptosis of tumor cells [J]. Journal of Practical Oncology, 2021, 35(2): 165-169.
[13]	LI Mingming, YUE Chenxi, ZHANG Menglin, HUANG Wenjuan, WANG Ruitao. Research progress on the relationship between Podoplanin-CLEC2 activation of platelets and tumors [J]. Journal of Practical Oncology, 2021, 35(2): 174-178.
[14]	BI Jiaqing, QIN Qian, MA Huihan, MA Meijie, FENG Qinmei. Research progress of threonine and tyrosine kinase in tumor [J]. Journal of Practical Oncology, 2021, 35(2): 188-192.
[15]	LIU Xuejing,XU Yanying. Research progress of B7-H6 in malignant tumors [J]. Journal of Practical Oncology, 2021, 35(1): 46-49.

5-Hydroxymethylcytosine and tumor

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments